This is an excerpt of an article on the same vaccine out of Korea:
"The vaccine in the fashion this winter, the Soviet A-type 'and' Hong Kong A-type ', and the possibility of new byeonyidoel flu' H5N1 type 'of bird flu 3 species was made based on a common internal proteins."
http://tinyurl.com/dhhv9d
THURSDAY, 29 JANUARY 2009
While many Chinese are affected by the H5N1 virus have died, the Japanese say finalizing a vaccine-resistant mutations of the avian influenza and likely to avoid a catastrophic pandemic for humans.
AFP - Japanese researchers claimed Thursday to have found a vaccine that might work against possible mutations of the avian influenza virus and prevent a catastrophic pandemic.
The team tested the vaccine on mice that had been implanted human genes and experience has confirmed that the treatment works even when mutation of the virus, said Tetsuya Uchida, a researcher at the National Institute of Diseases infectious.
According to these scientists, this discovery could help prevent a pandemic if the H5N1 avian influenza mutait to be transmitted from humans, a hypothesis which threatens millions of deaths in World Health Organization (WHO ).
The usual vaccines against influenza are based on the protein that covers the envelope of the virus, but this protein is often subject to change, making the vaccine ineffective.
Japanese researchers have based their vaccine on internal virus proteins, which have little tendency to mutate, "said Uchida to AFP.
He warned however that it would take years to make the vaccine available, the testing to be carried out on mice and other animals, to ensure its safety, before trying it on men.
The researcher said that the vaccine was successfully tested on different flu viruses, including highly pathogenic H5N1 virus of avian influenza, but also on virus more "classic" type A
Tests were conducted this winter in Japan, but also in the USA, to measure the resistance of the virus most prevalent this season as Tamiflu, the antiviral used as marketed by the Swiss pharmaceutical group Roche.
The federal Centers for control and prevention of diseases, the American side, as the Ministry of Health, Japanese side, have warned that most of these type A viruses were resistant to Tamiflu.
The work of Japanese researchers is carried out jointly by specialists from the National Institute of Infectious Diseases, University of Hokkaido, the Saitama Medical University and the NOF chemical company, based in Tokyo.
The NOF has jumped by more than 20% at the Tokyo Stock Exchange as soon as the new known.
Similar attempts to develop vaccines, addressing in the virus rather than its envelope are underway elsewhere, including at the University of Oxford (United Kingdom), "said Uchida.
-snip-
No comments:
Post a Comment